+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the treatment of anemia in patients with chronic kidney disease CKD who are on hemodialysis. This Phase III, investigator-blinded, randomized, multicenter study compares two drugs, efepoetin alfa and darbepoetin alfa, to see how well they maintain hemoglobin levels in these patients. The study aims to maintain hemoglobin between 10.0 gdL and 12.0 gdL, which is important for managing anemia in CKD. Participants will be randomly assigned in a 21 ratio to receive either efepoetin alfa or darbepoetin alfa. Both drugs are given by intravenous injection, typically after dialysis sessions. Efepoetin alfa is administered weekly from Day 1 to Week 28, with possible interval changes to one or two weeks from Week 29 to Week 52 based on investigator judgment. The study consists of three periods screening up to 28 days, treatment about 52 weeks, and a 4-week follow-up with phone contacts up to Week 56 or the last visit. During the study, participants will undergo regular assessments including hemoglobin level monitoring to evaluate the mean change between Week 20 and Week 28. Safety and efficacy are closely observed, with dosages adjusted to maintain target hemoglobin levels. Follow-up will include phone contacts to monitor participants up to Week 56. The total participation duration is approximately one year, starting from screening through treatment and follow-up.

Age: 18Years +All GendersPhase 3
58 locations
P

Actively Recruiting

Researchers are observing the safety and effectiveness of Piqray Alpelisib in patients with advanced breast cancer in Korea. This observational study focuses on patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer who have progressed after prior endocrine therapy. The study aims to collect real-world data on Piqray use for up to 24 weeks. Participants prescribed Piqray will be followed during their treatment period, which lasts up to 24 weeks. If a participant stops taking Piqray or misses follow-up visits, all collected data until the last contact will be used. After treatment or early withdrawal, patients will have a safety follow-up for 30 days to monitor any adverse effects. During the study, researchers will collect information about side effects and treatment responses. They will review incidence of adverse events within 24 weeks and measure objective response rates and prescribed doses of Piqray combined with fulvestrant. Participants will be observed through visits and data collection over the treatment and follow-up periods to ensure comprehensive safety and effectiveness monitoring.

Age: 18Years - 100YearsAll Genders
19 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
S

Actively Recruiting

This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.

Age: 18Years +All Genders
59 locations
E

Actively Recruiting

Researchers are evaluating remibrutinib in adult participants with severe chronic pruritus of unknown origin CPUO, a condition causing persistent severe itching without a known cause. This phase 3, global, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of remibrutinib for this condition. Participants will undergo up to 60 weeks of study divided into four periods. After a screening period of up to 4 weeks, participants enter a 24-week double-blind phase receiving either remibrutinib or placebo. Then, a 28-week open-label phase follows, where all participants receive remibrutinib. Lastly, there is a 4-week treatment-free safety follow-up period. Throughout the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity. Researchers will monitor sleep disturbance related to itching, record adverse events, and evaluate treatment tolerability. The entire participation can last up to 60 weeks, including treatment and follow-up phases.

Age: 18Years +All GendersPhase 3
17 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of CnU capsule 500 mg in adults with biliary dyspepsia, a condition causing pain in the upper abdomen related to gallbladder and bile duct function. This Phase 4 clinical trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to carefully assess symptom improvement and overall safety. Participants are randomly assigned to receive either the CnU capsule 500 mg or a placebo capsule, taken orally once daily after meals for 24 weeks. The study uses a parallel design, with treatments given at about the same time each day. Both groups are monitored throughout the treatment period for changes in symptoms and quality of life. During the 24-week study, participants will be evaluated using the Global Overall Symptom Scale GOS at the start and at Week 24 to measure symptom improvement. Additional assessments include symptom scores and quality of life measures at baseline, Week 4, Week 12, and Week 24. The study team will monitor participant safety and treatment adherence throughout, with the goal of understanding the impact of CnU capsule on biliary dyspepsia symptoms.

Age: 19Years +All GendersPhase 4
8 locations
A

Actively Recruiting

Researchers are studying patients with cholesterol gallstones, specifically those with radiolucent gallstones, to assess the effectiveness and safety of the CnU capsule 750 mg. This phase 4 clinical trial compares this treatment to an active comparator, Ursa tablet, aiming to provide insights into dissolving gallstones and improving patient outcomes. Participants receive either CnU capsule combined with a placebo Ursa tablet or Ursa tablet combined with a placebo CnU capsule. Both treatments are taken orally three times a day after meals for a total duration of 24 weeks. The study includes a randomized, double-blind, parallel design to fairly evaluate and compare these treatments. Throughout the study, participants undergo assessments including abdominal ultrasonography and plain abdominal X-rays to monitor gallstone changes. Researchers measure the response to the dissolution therapy from the start to the end of treatment, focusing on complete and partial dissolution rates. Safety and efficacy are carefully monitored over the 24 weeks, with the total participation lasting until the studys completion in mid-2028.

Age: 19Years +All GendersPhase 4
13 locations
R

Actively Recruiting

Researchers are studying the effects of IN-115314 ointment in adults with mild to moderate atopic dermatitis. This phase 2 clinical trial aims to assess both how well the ointment works and how safe it is. The study compares two strengths of the ointment, 1% and 3%, against a placebo while monitoring skin condition changes using a standardized severity index. Participants will apply the assigned ointment twice daily for up to 56 days. The study includes three groups one using 1% ointment, another using 3% ointment, and a placebo group that applies placebo ointment for 28 days followed by 3% ointment for another 28 days. This approach helps evaluate the ointments effects over time and its pharmacokinetic properties. Throughout the study, participants will be regularly assessed for changes in their eczema severity using the Eczema Area and Severity Index EASI at 1, 2, and 4 weeks. Safety and side effects will also be closely monitored. The entire study period extends up to about two months, providing detailed information on treatment response and safety in adults with atopic dermatitis.

Age: 19Years +All GendersPhase 2
1 location
P

Actively Recruiting

This trial evaluates the safety and effectiveness of GSK4532990 in adults aged 18 to 70 who have alcohol-related liver disease, including those with advanced chronic liver disease. The study aims to understand how this drug affects liver health, including changes in liver stiffness and liver disease severity over time, compared to a placebo. It is a phase 2, double-blind, placebo-controlled trial sponsored by GlaxoSmithKline. Participants will be assigned to receive one of four doses of GSK4532990 or a placebo. The study uses a sequential design where dosing and treatment effects are monitored closely. Treatment and safety assessments are conducted up to 8 weeks, with liver measurements taken at baseline and at 52 weeks to evaluate long-term effects. During the trial, participants will undergo regular safety evaluations including monitoring for adverse events, heart and vital sign checks, and laboratory tests. Liver stiffness and disease severity scores will be measured at the start and after one year. Additional blood tests will assess drug levels and liver function. The total study participation includes initial screening, treatment, and follow-up visits lasting up to 52 weeks.

Age: 18Years - 70YearsAll GendersPhase 2
140 locations
U

Actively Recruiting

This research focuses on patients who have had an Embolic Stroke of Undetermined Source ESUS and have received an Implantable Cardiac Monitor ICM. It evaluates the use of an artificial intelligence tool called SmartECG-AF, which analyzes standard 12-lead ECGs taken during normal heart rhythm to predict the risk of developing atrial fibrillation AF. The study aims to understand if this AI tool can help identify which patients are more likely to experience AF and major cardiovascular events after ESUS. Participants will be divided into two groups based on the AIs risk assessment a High Risk group and a Low to Intermediate Risk group. The study will follow these groups over time to compare the frequency and timing of AF events detected by the ICM. This multicenter, prospective study will also explore the relationship between the AI risk scores and the occurrence of major adverse cardiovascular events, helping to assess the value of AI-guided risk stratification. During the study, patients baseline ECGs will be analyzed by the AI algorithm, and their heart rhythm will be monitored continuously through the ICM. Researchers will track the time to AF events and record any major cardiovascular incidents over a follow-up period of up to 12 months. Participants will be monitored for safety and clinical outcomes, providing data on how well the AI tool predicts cardiac risks in this population.

Age: 30Years +All Genders
5 locations

1-10 of 23

1